Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
Bart J. Kramers, Maatje D.A. van Gastel, Wendy E. Boertien, et al.
American Journal of Kidney Diseases (2018) Vol. 73, Iss. 3, pp. 354-362
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
Roman‐Ulrich Müller, A. Lianne Messchendorp, Henrik Birn, et al.
Nephrology Dialysis Transplantation (2021) Vol. 37, Iss. 5, pp. 825-839
Open Access | Times Cited: 96
Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease
Bart J. Kramers, Iris W. Koorevaar, Joost P.H. Drenth, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. 989-998
Open Access | Times Cited: 55
The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles
Yi Huang, Kairui Jiang, Xuting Zhang, et al.
Bioengineering & Translational Medicine (2020) Vol. 5, Iss. 3
Open Access | Times Cited: 55
Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD
Bart J. Kramers, Iris W. Koorevaar, Maatje D.A. van Gastel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 4, pp. 507-517
Open Access | Times Cited: 29
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Thomas Bais, Ron T. Gansevoort, Esther Meijer
Drugs (2022) Vol. 82, Iss. 10, pp. 1095-1115
Open Access | Times Cited: 26
Treatment of Autosomal Dominant Polycystic Kidney Disease
Sara S. Jdiaa, Reem A. Mustafa, Alan S.L. Yu
American Journal of Kidney Diseases (2024)
Open Access | Times Cited: 5
Longitudinal assessment of measured and estimated glomerular filtration-rate in autosomal dominant polycystic kidney disease: Real practice experience
Juan Marcelo Fernández, José Carlos Rodríguez‐Pérez, Mercedes Lorenzo-Medina, et al.
World Journal of Nephrology (2025) Vol. 14, Iss. 1
Closed Access
Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
Matthew Gittus, Helen Haley, Tess Harris, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Therapeutic Potential of Urinary Extracellular Vesicles in Delivering Functional Proteins and Modulating Gene Expression for Genetic Kidney Disease
Yi Huang, Ali Osouli, Hui Li, et al.
Biomaterials (2025), pp. 123296-123296
Closed Access
Biological Efficacy and Safety of Niacinamide in Patients With ADPKD
Mireille El Ters, Xia Zhou, Rebecca J. Lepping, et al.
Kidney International Reports (2020) Vol. 5, Iss. 8, pp. 1271-1279
Open Access | Times Cited: 31
Investigation of Basolateral Targeting Micelles for Drug Delivery Applications in Polycystic Kidney Disease
Yi Huang, Ali Osouli, Jessica Pham, et al.
Biomacromolecules (2024) Vol. 25, Iss. 5, pp. 2749-2761
Closed Access | Times Cited: 3
Oral delivery of nanomedicine for genetic kidney disease
Yi Huang, Jonathan Wang, Valeria Mancino, et al.
PNAS Nexus (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 3
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Ioannis Bellos
Therapeutics and Clinical Risk Management (2021) Vol. Volume 17, pp. 649-656
Open Access | Times Cited: 23
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon
Julie Zhou, Vicente E. Torres
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 3, pp. 245-260
Closed Access | Times Cited: 8
The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
Kiyotaka Uchiyama, Chigusa Kitayama, Akane Yanai, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 20
HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial
Thomas Bais, Esther Meijer, Bart J. Kramers, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
Ronald D. Perrone, Arlene B. Chapman, Dorothee Oberdhan, et al.
Kidney International Reports (2020) Vol. 5, Iss. 6, pp. 801-812
Open Access | Times Cited: 18
Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease
Taro Akihisa, Hiroshi Kataoka, Shiho Makabe, et al.
Clinical and Experimental Nephrology (2022) Vol. 26, Iss. 6, pp. 540-551
Closed Access | Times Cited: 9
Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
Polina Todorova, Sita Arjune, Claudia Hendrix, et al.
Kidney International Reports (2023) Vol. 8, Iss. 8, pp. 1616-1626
Open Access | Times Cited: 4
Recent Advances in Sodium Magnetic Resonance Imaging and Its Future Role in Kidney Disease
Alireza Akbari, Christopher W. McIntyre
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4381-4381
Open Access | Times Cited: 4
The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan
Pao‐Wen Yen, Y.-M. Chen, Wei Wang, et al.
Nephrology (2024) Vol. 29, Iss. 5, pp. 245-258
Open Access | Times Cited: 1
Measured and Estimated Glomerular Filtration Rate to Evaluate Rapid Progression and Changes over Time in Autosomal Polycystic Kidney Disease: Potential Impact on Therapeutic Decision-Making
Rosa Miquel-Rodríguez, Beatriz González-Toledo, María-Vanessa Pérez-Gómez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 5036-5036
Open Access | Times Cited: 1
Vaptans or voluntary increased hydration to protect the kidney: how do they compare?
Lise Bankir, Dominique Guerrot, Daniel G. Bichet
Nephrology Dialysis Transplantation (2021) Vol. 38, Iss. 3, pp. 562-574
Open Access | Times Cited: 10
Optical-Controlled Kinetic Switch: Fine-Tuning of the Residence Time of an Antagonist Binding to the Vasopressin V2 Receptor in In Vitro, Ex Vivo, and In Vivo Models of ADPKD
Xiaoke Gu, Haoxing Yuan, Wenchao Zhao, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 2, pp. 1454-1466
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top